Virax Holdings (ASX:VHL) has changed its name to Prescient Therapeutics and is expected to start trading as (ASX:PTX) on 15th December 2014.
Prescient's flagship asset is its Co-X-Gene anti-cancer technology.
The strength of the technology was confirmed earlier this year by licensing partner Transgene, demonstrating topline results for their Phase 2B clinical trial using Co-X-Gene, conducted under an option with Novartis (NYSE:NVS), in the treatment of Non-Small Cell Lung Cell Cancer.
Novartis is the largest pharmaceutical company in the world with a capitalisation of almost $200 billion, and Transgene’s immunotherapeutic product TG4010, utilizes Virax's Co-X-Gene platform.
Transgene’s activities have also gained the interest of major pharmaceutical company Sanofi (NYSE:SNY) capitalised at over $130 billion.
Sanofi and Transgene have subsequently launched construction of a manufacturing platform for the production of viral vectors, as utilized by Transgene’s immunotherapeutic product.
Medical conditions outside of cancer are also being targeted, including potential veterinary applications.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.